{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:20:36Z","timestamp":1789572036699,"version":"build-2803163510"},"reference-count":15,"publisher":"Akademiai Kiado Zrt.","issue":"51","license":[{"start":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T00:00:00Z","timestamp":1766275200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2025,12,21]]},"abstract":"\n Bevezet\u00e9s:<\/jats:italic>\n A radik\u00e1lis prostatectomia ut\u00e1ni biok\u00e9miai ki\u00fajul\u00e1s\n eset\u00e9n az Eur\u00f3pai Urol\u00f3gus T\u00e1rsas\u00e1g ir\u00e1nyelvei szerint PSMA PET\/CT k\u00e9palkot\u00e1s\n javasolt. Ez a diagnosztikai lehet\u0151s\u00e9g az elm\u00falt \u00e9vekben Magyarorsz\u00e1gon is\n el\u00e9rhet\u0151v\u00e9 v\u00e1lt.\n C\u00e9lkit\u0171z\u00e9s:<\/jats:italic>\n Munk\u00e1nk c\u00e9lja egy\n rutindiagnosztik\u00e1ra is alkalmas,\n 18<\/jats:sup>\n F-ral jel\u00f6lt PSMA-radiofarmakon\n (\n 18<\/jats:sup>\n F-JK-PSMA-7) klinikai alkalmazhat\u00f3s\u00e1g\u00e1nak vizsg\u00e1lata volt a\n daganat biok\u00e9miai ki\u00fajul\u00e1sa eset\u00e9n.\n M\u00f3dszer:<\/jats:italic>\n Retrospekt\u00edv m\u00f3don\n elemezt\u00fcnk 67 beteget, akikn\u00e9l definit\u00edv ter\u00e1pia (radik\u00e1lis prostatectomia \u00b1\n adjuv\u00e1ns kezel\u00e9s) ut\u00e1n emelkedett PSA-szint (>0,2 ng\/ml) miatt t\u00f6rt\u00e9nt\n 18<\/jats:sup>\n F-JK-PSMA-7 PET\/CT vizsg\u00e1lat. A k\u00e9palkot\u00f3 eredm\u00e9nyeket lok\u00e1lis\n recid\u00edva, nyirokcsom\u00f3- \u00e9s t\u00e1voli \u00e1tt\u00e9tek szerint \u00e9rt\u00e9kelt\u00fck. A betegeket k\u00e9t-k\u00e9t\n alcsoportra osztottuk a PSA-szint (1 ng\/ml k\u00fcsz\u00f6b\u00e9rt\u00e9k) \u00e9s a PSA-dupl\u00e1z\u00f3d\u00e1si id\u0151\n (PSAdt, 6 h\u00f3nap) alapj\u00e1n. Pozit\u00edv esetekben vizsg\u00e1ltuk a legintenz\u00edvebb laesi\u00f3k\n maxim\u00e1lis standardiz\u00e1lt felv\u00e9teli (SUV\n max<\/jats:sub>\n ) \u00e9rt\u00e9ke \u00e9s a PSA, illetve a\n PSAdt k\u00f6z\u00f6tti kapcsolatot.\n Eredm\u00e9nyek:<\/jats:italic>\n 51 betegn\u00e9l (76,1%)\n tal\u00e1ltunk PSMA-avid, prostatacarcinom\u00e1ra utal\u00f3 elv\u00e1ltoz\u00e1st. A felismer\u00e9si ar\u00e1ny\n szignifik\u00e1nsan nagyobb volt az 1 ng\/ml feletti PSA-\u00e9rt\u00e9k\u0171 betegek k\u00f6r\u00e9ben (88,1%\n vs.<\/jats:italic>\n 56%; p = 0,019). A pozit\u00edv esetek\n SUV\n max<\/jats:sub>\n -\u00e9rt\u00e9kei szint\u00e9n nagyobbnak bizonyultak a PSA>1 ng\/ml,\n valamint a r\u00f6videbb PSAdt-\u00e9rt\u00e9k\u0171 csoportban.\n Megbesz\u00e9l\u00e9s:<\/jats:italic>\n Eredm\u00e9nyeink al\u00e1t\u00e1masztj\u00e1k a PSMA PET\/CT klinikai jelent\u0151s\u00e9g\u00e9t a\n prostatacarcinoma biok\u00e9miai ki\u00fajul\u00e1sa eset\u00e9n. A PSA-szint mark\u00e1ns hat\u00e1sa a\n felismer\u00e9si ar\u00e1nyra \u00e9s a PSMA-avidit\u00e1s m\u00e9rt\u00e9k\u00e9re indokolhatja egy predikt\u00edv\n PSA-k\u00fcsz\u00f6b\u00e9rt\u00e9k meghat\u00e1roz\u00e1s\u00e1t. A PSAdt ezzel szemben korl\u00e1tozottabb predikt\u00edv\n \u00e9rt\u00e9ket mutatott. A m\u00f3dszer \u00e9rz\u00e9kenys\u00e9ge \u00e9s a\n 18<\/jats:sup>\n F-radiofarmakon\n technikai el\u0151nyei a gyakorlatban is j\u00f3l \u00e9rv\u00e9nyes\u00fcltek.\n K\u00f6vetkeztet\u00e9s:<\/jats:italic>\n A\n 18<\/jats:sup>\n F-JK-PSMA-7 PET\/CT \u00e9rz\u00e9keny\n \u00e9s klinikailag relev\u00e1ns eszk\u00f6z a prosztatar\u00e1k biok\u00e9miai relapsus\u00e1nak\n kimutat\u00e1s\u00e1ra. A PSA-szint alapj\u00e1n t\u00f6rt\u00e9n\u0151 betegstratifik\u00e1ci\u00f3 jav\u00edthatja a\n vizsg\u00e1lat hat\u00e9konys\u00e1g\u00e1t. Orv Hetil. 2025; 166(51): 2018\u20132023.\n <\/jats:p>","DOI":"10.1556\/650.2025.33441","type":"journal-article","created":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T09:00:11Z","timestamp":1766307611000},"page":"2018-2023","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":1,"title":["18F-PSMA PET\/CT vizsg\u00e1lat prosztatar\u00e1k biok\u00e9miai ki\u00fajul\u00e1s\u00e1t k\u00f6vet\u0151en"],"prefix":"10.1556","volume":"166","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2680-6573","authenticated-orcid":true,"given":"Domonkos","family":"N\u00e1dasdy-Horv\u00e1th","sequence":"first","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Orvosi K\u00e9palkot\u00f3 Klinika, Nukle\u00e1ris Medicina Tansz\u00e9k Budapest, \u00dcll\u0151i \u00fat 26., 1085 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rton","family":"Piroska","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Orvosi K\u00e9palkot\u00f3 Klinika, Nukle\u00e1ris Medicina Tansz\u00e9k Budapest, \u00dcll\u0151i \u00fat 26., 1085 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e1ndor","family":"Czibor","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Orvosi K\u00e9palkot\u00f3 Klinika, Nukle\u00e1ris Medicina Tansz\u00e9k Budapest, \u00dcll\u0151i \u00fat 26., 1085 Magyarorsz\u00e1g"},{"name":"Pozitron Medical Diagnosztika K\u00f6zpont Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Varga","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Orvosi K\u00e9palkot\u00f3 Klinika, Nukle\u00e1ris Medicina Tansz\u00e9k Budapest, \u00dcll\u0151i \u00fat 26., 1085 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyula","family":"T\u00f3th","sequence":"additional","affiliation":[{"name":"Pozitron Medical Diagnosztika K\u00f6zpont Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szabolcs","family":"Szak\u00e1ll","sequence":"additional","affiliation":[{"name":"Pozitron Medical Diagnosztika K\u00f6zpont Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e1nos","family":"Szalontai","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Urol\u00f3giai Klinika Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikl\u00f3s","family":"Sz\u0171cs","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Urol\u00f3giai Klinika Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Nyir\u00e1dy","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Urol\u00f3giai Klinika Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Gy\u00f6rke","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Orvosi K\u00e9palkot\u00f3 Klinika, Nukle\u00e1ris Medicina Tansz\u00e9k Budapest, \u00dcll\u0151i \u00fat 26., 1085 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Kenessey I, Szil\u00e1gyi I, Dobozi M, et al. The role of National Cancer\n Registry in the assessment of Hungarian cancer epidemiology. [A Nemzeti\n R\u00e1kregiszter szerepe a hazai daganatos epidemiol\u00f3giai helyzet felm\u00e9r\u00e9s\u00e9ben.] Orv\n Hetil. 2024; 165: 925-932. [Hungarian]\n https:\/\/doi.org\/10.1556\/650.2024.33062","DOI":"10.1556\/650.2024.33062"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Kenessey I, W\u00e9ber A, Nagy P, et al. An unfavorable trend in the\n incidence of prostate cancer in Hungary - preliminary results from the National\n Cancer Registry. [Kedvez\u0151tlen tendencia a prosztatar\u00e1k hazai incidenci\u00e1j\u00e1ban - a\n Nemzeti R\u00e1kregiszter el\u0151zetes eredm\u00e9nyei.] Orv Hetil. 2025; 166: 1238-1239.\n [Hungarian] https:\/\/doi.org\/10.1556\/650.2025.31M","DOI":"10.1556\/650.2025.31M"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Tenke P, Bodoky Gx, G\u00e9czi L, et al. Criteria of a standard and\n high-quality care of prostate cancer for long-term survival of patients in good\n quality of life. [A prosztatar\u00e1k korszer\u0171 ell\u00e1t\u00e1s\u00e1nak felt\u00e9telrendszere a\n betegek j\u00f3 \u00e9letmin\u0151s\u00e9gben elt\u00f6lt\u00f6tt, hosszabb t\u00fal\u00e9l\u00e9s\u00e9\u00e9rt.] Magy Urol. 2021; 33:\n 104-124. [Hungarian]\n https:\/\/doi.org\/10.22591\/magyurol.2021.3.tenkep.104","DOI":"10.22591\/magyurol.2021.3.tenkep.104"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Tourinho-Barbosa R, Srougi V, Nunes-Silva I, et al. Biochemical\n recurrence after radical prostatectomy: what does it mean? Int Braz J Urol.\n 2018; 44: 14-21.\n https:\/\/doi.org\/10.1590\/s1677-5538.ibju.2016.0656","DOI":"10.1590\/s1677-5538.ibju.2016.0656"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Houshmand S, Lawhn-Heath C, Behr S. PSMA PET imaging in the\n diagnosis and management of prostate cancer. Abdom Radiol (NY) 2023; 48:\n 3610-3623.\n https:\/\/doi.org\/10.1007\/s00261-023-04002-z","DOI":"10.1007\/s00261-023-04002-z"},{"key":"R6","unstructured":"K\u00fcronya Zs, \u00c1goston P, Jorgo K, et al. The effect of PSMA PET\/CT\n performed in primary staging on the clinical decision. [Primer staging r\u00e9szek\u00e9nt\n v\u00e9gzett PSMA PET\/CT hat\u00e1sa a klinikai d\u00f6nt\u00e9sre.] Magy Onkol. 2025; 69: 203-207\n [Hungarian]"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Farkas I, Besenyi Z, Mar\u00e1z A, et al. Initial experiences with\n 99mTc-PSMA-SPECT\/CT in patients with prostate cancer. [Kezdeti\n tapasztalatok a 99mTc-PSMA-SPECT\/CT-vel prosztatar\u00e1kos betegekben.]\n Orv Hetil. 2018; 159: 1433-1440. [Hungarian]\n https:\/\/doi.org\/10.1556\/650.2018.31128","DOI":"10.1556\/650.2018.31128"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Mottet N, Van Den Bergh RC, Briers E, et al.\n EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer - 2020 update. Part 1:\n screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;\n 79: 243-262.\n https:\/\/doi.org\/10.1016\/j.eururo.2020.09.042","DOI":"10.1016\/j.eururo.2020.09.042"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"O\u2019Keefe DS, Bacich DJ, Huang SS, et al. A perspective on the\n evolving story of PSMA biology, PSMA-based imaging, and endoradiotherapeutic\n strategies. J Nucl Med. 2018; 59: 1007-1013.\n https:\/\/doi.org\/10.2967\/jnumed.117.203877","DOI":"10.2967\/jnumed.117.203877"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Wu Q, Bates A, Guntur P, et al. Detection rate of PSMA PET using\n different ligands in men with biochemical recurrent prostate cancer following\n radical treatment: a systematic review and meta-analysis of prospective studies.\n Acad Radiol. 2024; 31: 544-563.\n https:\/\/doi.org\/10.1016\/j.acra.2023.08.044","DOI":"10.1016\/j.acra.2023.08.044"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Chandekar KR, Satapathy S, Bal C. Utility of novel radiohybrid PSMA\n ligands in PET imaging of biochemical recurrence of prostate cancer - a\n systematic review and meta-analysis. Clin Nucl Med. 2025; 50: e323-e330.\n https:\/\/doi.org\/10.1097\/RLU.0000000000005641","DOI":"10.1097\/RLU.0000000000005641"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Eiber M, Kroenke M, Wurzer A, et al. 18F-rhPSMA-7 PET for\n the detection of biochemical recurrence of prostate cancer after radical\n prostatectomy. J Nucl Med. 2020; 61: 696-701.\n https:\/\/doi.org\/10.2967\/jnumed.119.234914","DOI":"10.2967\/jnumed.119.234914"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Giesel FL, Knorr K, Spohn F, et al. Detection efficacy of\n 18F-PSMA-1007 PET\/CT in 251 patients with biochemical recurrence\n of prostate cancer after radical prostatectomy. J Nucl Med. 2019; 60: 362-368.\n https:\/\/doi.org\/10.2967\/jnumed.118.212233","DOI":"10.2967\/jnumed.118.212233"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Loeff CC, van Gemert W, Priv\u00e9 BM, et al. [18F]PSMA-1007\n PET for biochemical recurrence of prostate cancer, a comparison with\n [18F]Fluciclovine. EJNMMI Reports 2024; 8: 38.\n https:\/\/doi.org\/10.1186\/s41824-024-00228-2","DOI":"10.1186\/s41824-024-00228-2"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Masselli G, Sollaku S, De Angelis C, et al. 68Ga-PSMA\n PET\/CT in recurrent prostate cancer after radical prostatectomy using PSMA-RADS\n version 2.0. Diagnostics 2024; 14: 1291.\n https:\/\/doi.org\/10.3390\/diagnostics14121291","DOI":"10.3390\/diagnostics14121291"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/166\/51\/article-p2018.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/166\/51\/article-p2018.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/166\/51\/article-p2018.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T09:00:14Z","timestamp":1766307614000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/166\/51\/article-p2018.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,21]]},"references-count":15,"journal-issue":{"issue":"51"},"URL":"https:\/\/doi.org\/10.1556\/650.2025.33441","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,21]]}}}